Nevirapine
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of HIV infection in combination with other antiretroviral agents.
- Due to increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.
NON-FDA APPROVED USES
- Single dose at time of delivery to prevent perinatal transmission (widely used in developing countries, but risk of NNRTI resistance; combination therapy preferred when available). Risk of hepatitis for women with CD4 >250 does not apply to single dose NVP.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of HIV infection in combination with other antiretroviral agents.
- Due to increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.
NON-FDA APPROVED USES
- Single dose at time of delivery to prevent perinatal transmission (widely used in developing countries, but risk of NNRTI resistance; combination therapy preferred when available). Risk of hepatitis for women with CD4 >250 does not apply to single dose NVP.
There's more to see -- the rest of this entry is available only to subscribers.